Effect of sibutramine on weight management and metabolic control in type 2 diabetes: A meta-analysis of clinical studies

Diabetes Care

Volumn 28, Issue 4, 2005, Pages 942-949

  Vettor, Roberto ^a   Serra, Roberto ^a   Fabris, Roberto ^a   Pagano, Claudio ^a   Federspil, Giovanni ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SIBUTRAMINE;

BODY WEIGHT; CLINICAL TRIAL; DIABETIC OBESITY; DIASTOLIC BLOOD PRESSURE; GLUCOSE BLOOD LEVEL; HEART RATE; HUMAN; META ANALYSIS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

APPETITE DEPRESSANTS; BODY WEIGHT; CYCLOBUTANES; DIABETES MELLITUS, TYPE 2; HUMANS; RANDOMIZED CONTROLLED TRIALS; TRIGLYCERIDES;

EID: 15944371577     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.28.4.942     Document Type: Review

References (38)

1. Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291:2847-2850, 2004
2. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287:356-359, 2002
3. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, the DECODE Study Group: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 164:1066-1076, 2004
4. Shaughnessy AF, Slawson DC: What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes (Review). BMJ 327:266, 2003
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
6. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
7. UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
8. Verhagen AP, de Vet HC, de Bie RA, Kessels AG, Boers M, Bouter LM, Knipschild PG: The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. J Clin Epidemiol 51:1235-1241, 1998
9. Hedges LV, Olkin I: Statistical Methods for Meta-Analysis. Harcourt Brace Janovich, ed. Orlando, FL, Academic Press, 1985
10. Serrano-Rios M, Melchionda N, Moreno-Carretero E, the Spanish Investigators: Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 19:119-124, 2002
11. McNulty SJ, Ur E, Williams G, the Multicenter Sibutramine Study Group: A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 26:125-131, 2003
12. Fujioka K, Seaton TB, Rowe E, Jelinek CA, Raskin P, Lebovitz HE, Weinstein SP, the Sibutramine/Diabetes Clinical Study Group: Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2:175-187, 2000
13. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J: Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab 2:105-112, 2000
14. Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N: Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care 24:1957-1960, 2001
15. Sanchez-Reyes L, Fanghanel G, Yamamoto J, Martinez-Rivas L, Campos-Franco E, Berber A: Use of sibutramine in overweight adult Hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 26:1427-1435, 2004
16. Kaukua JK, Pekkarinen TA, Rissanen AM: Health-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int Obes Relat Metab Disord 28:600-605, 2004
17. Redmon JB, Raatz SK, Reck KP, Swanson JE, Kwong CA, Fan Q, Thomas W, Bantle JP: One-year outcome of a combination of weight loss therapies for subjects with type 2 diabetes: a randomized trial. Diabetes Care 26:2505-2511, 2003
18. Grundy SM: Obesity, metabolic syndrome, and cardiovascular disease. J Clin Endocrinol Metab 89:2595-2600, 2004
19. Bray GA: Medical consequences of obesity. J Clin Endocrinol Metab 89:2583-2589, 2004
20. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, McLanahan SM, Kirkeeide RL, Brand RJ, Gould KL: Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 336:129-133, 1990
21. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J: Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 164:1395-1404, 2004
22. James WP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WH, Van Gaal LF: Effect of sibutramine on weight maintenance after weight loss: a randomised trial: STORM Study Group: Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356:2119-2125, 2000
23. Glazer G: Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety. Arch Intern Med 161:1814-1824, 2001
24. Wirth A, Krause J: Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286:1331-1339, 2001
25. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N: Association of Hemoglobin Alc with cardiovascular disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Ann Intern Med 141:413-420, 2004
26. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
27. Libby P, Plutzky J: Diabetic macrovascular disease: the glucose paradox? Circulation 106:2760-2763, 2002
28. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104:3046-3051, 2001
29. Geiss LS, Rolka DB, Engelgau MM: Elevated blood pressure among U.S. adults with diabetes, 1988-1994. Am J Prev Med 22:42-48, 2002
30. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572, 2003
31. Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels J, Ryan DH, Schwartz SL, Scheinbaum ML, Seaton TB: Sibutramine produces dose-related weight loss. Obes Res 7:189-198, 1999
32. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD: Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160:2185-2191, 2000
33. McMahon FG, Weinstein SP, Rowe E, Ernst KR, Johnson F, Fujioka K, the Sibutramine in Hypertensives Clinical Study Group: Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Hum Hypertens 16:5-11, 2002
34. Hazenberg BP: Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 94:152-158, 2000
35. Zannad F, Gille B, Grentzinger A, Bruntz JF, Hammadi M, Boivin JM, Hanotin C, Igau B, Drouin P: Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 144:508-515, 2002
36. Kim SH, Lee YM, Jee SH, Nam CM: Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 11:1116-1123, 2003
37. Birkenfeld AL, Schroeder C, Boschmann M, Tank J, Franke G, Luft FC, Biaggioni I, Sharma AM, Jordan J: Paradoxical effect of sibutramine on autonomic cardiovascular regulation. Circulation 106:2459, 2002
38. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G: Sympathetic activation in obese normotensive subjects. Hypertension 25:560-563, 1995